A phase II trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma (KDOG 0501 P2)
Phase 2
- Conditions
- locally advanced esophageal carcinoma
- Registration Number
- JPRN-UMIN000002029
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1. History of serious drug hypersensitivity 2. Active gastrointestinal bleeding 3. Active infection 4. Severe complication (interstitial pneumonia or pulmonary fibrosis, poorly controlled diabetes mellitus, heart failure, renal failure, liver cirrhosis or etc) 5. Active synchronous or metachronous malignancy other than carcinoma in situ. 6. Mental disorders being treated with antipsychotic agents or requiring treatment 7. Pregnant or lactation women, or women with the possibility of the pregnancy 8. Men who want let to pregnancy 9. Patients who are judged inappropriate for the entry into the study by the investigater
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method complete response rate
- Secondary Outcome Measures
Name Time Method Response rate Adverse events Progression free survival(PFS) Overall Survival(OS)